Health

Add as a preferred source on Google

Apotex Launches Axitinib After FDA’s First Generic Approval for INLYTA

Glenmark also announced a Nov. 16 launch of an authorized generic; the announcements do not establish which product reached pharmacies first.

Updated 2 min read
A pharmacy technician handles a prescription bottle at an oncology pharmacy in Weston, Florida. / EconoTimes.ai
A pharmacy technician handles a prescription bottle at an oncology pharmacy in Weston, Florida. / EconoTimes.ai

Apotex Health Corp. said it launched 1 mg and 5 mg axitinib tablets in the United States on Nov. 16, adding a generic option for advanced kidney cancer more than a year after U.S. regulators approved its application.

The Food and Drug Administration approved Apotex’s abbreviated new drug application, or ANDA, No. 211650, on Oct. 30, 2025, for prescription tablets in both strengths. The FDA’s 2025 first-generic list identifies Apotex’s application as the first generic approval for INLYTA, Pfizer’s brand-name axitinib. The agency says approval allows marketing but does not guarantee immediate availability.

Glenmark Pharmaceuticals Inc., USA, also announced a Nov. 16 launch of 1 mg and 5 mg axitinib tablets, describing its product as an authorized generic version of INLYTA. The companies announced launches on the same date, but their statements do not establish when either medicine reached pharmacies or which was available first.

Axitinib is used to treat advanced renal cell carcinoma, which the National Cancer Institute identifies as the kidney cancer diagnosis seen most often among adults. Apotex’s announcement describes use after failure of one prior systemic therapy. The FDA’s first-generic list also includes an abbreviated first-line combination indication with avelumab, while the agency’s application page does not provide Apotex’s full generic label. The current INLYTA label also lists a first-line combination with pembrolizumab.

Apotex lists 180 tablets per bottle for its 1 mg strength (NDC 60505-4427-8) and 60 tablets per bottle for its 5 mg strength (NDC 60505-4428-6). The company framed the launch as supporting access to affordable treatment options. “For patients, access to affordable treatment options is an important consideration throughout their care journey,” said Christine Baeder, president of Apotex USA and LATAM. Neither company disclosed a price or estimated savings, so the effect on patient and payer costs is not established.

Apotex’s announcement lists potential serious risks including high blood pressure, blood clots, bleeding, heart failure, liver toxicity and fetal harm.

Related articles

View all